Stereotaxis, Inc.: A Closer Look at Their 2025 Performance and Future Direction

Hello investors! Let's dive into the key takeaways from Stereotaxis, Inc.'s latest annual report (Form 10-K) for the fiscal year ending December 31, 2025. This summary aims to give you a clear picture of their business, financial health, and what's on the horizon.

What Does Stereotaxis Do?

Stereotaxis, Inc. (NYSE American: STXS) develops pioneering robotic magnetic navigation systems for interventional cardiology. These systems primarily treat complex arrhythmias, such as atrial fibrillation. Flagship products like the Niobe® EP Navigation System and the Genesis RMN® System empower physicians to precisely control catheters during delicate cardiac procedures, improving patient outcomes and reducing radiation exposure.

Company Status and Market Presence

Stereotaxis trades on the NYSE American exchange. The company qualifies as a "smaller reporting company" and a "non-accelerated filer." This classification means Stereotaxis had a public float (the value of shares available to regular investors, excluding insiders) of approximately $150.3 million as of June 30, 2025. Approximately 97.2 million shares were outstanding as of February 28, 2026. These designations permit Stereotaxis to comply with certain reporting requirements with less detail than larger companies, potentially leading to fewer disclosures on internal controls or executive compensation.

2025 Financial Performance Highlights

For the fiscal year ending December 31, 2025, Stereotaxis reported the following:

• Revenue: Total revenue reached $34.5 million, a 5% increase from $32.8 million in the previous year. Increased recurring revenue from procedure volumes and service contracts primarily drove this growth.
• Net Loss: The company reported a net loss of $18.2 million, or $0.19 per share. This marks an improvement from the $22.5 million net loss, or $0.23 per share, reported in 2024. While not yet cash flow positive from operations, this result indicates progress towards profitability.

Management's Discussion & Analysis (MD&A) Highlights

Management's Discussion & Analysis (MD&A) highlights several key points:

• Revenue Growth Drivers: Higher utilization of existing robotic systems and growth in service contract revenue fueled the revenue increase. This reflects an expanding installed base and rising procedural volumes.
• Net Loss Reduction: Revenue growth, combined with effective management of operating expenses and improved operational efficiencies, drove the reduction in net loss. However, significant ongoing investments in research and development (R&D) for next-generation platforms partially offset these gains.
• Strategic Priorities: Stereotaxis continues to prioritize strategic R&D investments to maintain its technological leadership and expand its product portfolio.
• Operational Challenges & Mitigation: Management addressed the impact of global supply chain challenges and inflationary pressures on the cost of goods sold and operating expenses. The company implemented mitigation strategies throughout the year to counter these effects.
• Accounting Policies: Management reviewed critical accounting policies, such as revenue recognition and the valuation of long-lived assets, confirming their consistent application.

Financial Health and Liquidity

Stereotaxis concluded the year with $25.7 million in cash and cash equivalents, a decrease from $35.1 million at the end of 2024. This reduction reflects ongoing investments in research and development and operational expenses.

The company maintained a manageable debt load, primarily a term loan facility with an outstanding balance of $10.0 million at year-end. Management actively focused on working capital, diligently managing inventory levels and accounts receivable.

While Stereotaxis believes its current cash resources, combined with anticipated revenue growth, will fund operations for at least the next 12 months, the company acknowledges that continued operating losses may require additional capital in the future. This capital would support long-term growth initiatives and the path to profitability. Capital expenditures for the year primarily funded R&D equipment and system installations.

Future Outlook

Stereotaxis achieved several key advancements in 2025:

• Product Innovation: The company continued significant investment in its next-generation Genesis RMN platform, making substantial progress toward expanding its clinical applications beyond electrophysiology.
• Market Expansion: Stereotaxis successfully installed 5 new Niobe EP systems worldwide, growing its total installed base to over 120 systems. The company also expanded its commercial presence in key European markets.
• Partnerships: Stereotaxis announced a strategic collaboration with a leading medical device manufacturer to integrate its robotic technology with advanced imaging solutions, enhancing procedural efficiency.
• Outlook for 2026: Management anticipates continued revenue growth of 7-10%, driven by new system sales and increasing utilization of existing systems. They also project a further reduction in net loss as they scale operations and control costs, with a long-term goal of achieving profitability within the next two to three years.

Competitive Position

Stereotaxis operates within the highly specialized and competitive medical robotics and electrophysiology markets. Its primary competitive advantage stems from its unique robotic magnetic navigation technology. This technology provides physicians with precise, remote control of catheters, potentially leading to improved patient outcomes, reduced radiation exposure for both patients and clinicians, and enhanced procedural consistency. This differentiated approach distinguishes Stereotaxis from traditional manual catheter ablation techniques and other robotic systems employing different control mechanisms.

However, the company faces significant competition from larger, well-established medical device companies. These competitors often possess greater financial resources, broader product portfolios, and extensive sales and marketing infrastructure. Additionally, alternative treatment modalities and new entrants developing innovative technologies also pose competitive threats. Stereotaxis's ability to maintain and grow its market share relies on continuous innovation, strong clinical evidence, effective commercialization strategies, and favorable reimbursement trends.

Key Risks for Investors

Investors should be aware of the following potential risks:

• Regulatory Approval: As a medical device company, Stereotaxis depends heavily on obtaining and maintaining regulatory approvals (e.g., FDA, CE Mark) for its products. This process can be lengthy and uncertain.
• Market Adoption: Widespread adoption of robotic magnetic navigation systems relies on physician acceptance, strong clinical evidence, and favorable reimbursement policies. These factors may not materialize as quickly as anticipated.
• Competition: The medical robotics and electrophysiology markets are highly competitive, with established players and new entrants continually innovating.
• Funding and Liquidity: While the company holds cash, continued operating losses mean Stereotaxis may require additional capital in the future to fund operations, research, and expansion. This could dilute existing shareholders.